Peptide motifs for cell-surface intervention: Application to anti-infective and biopharmaceutical development

BioDrugs

Volumn 19, Issue 4, 2005, Pages 261-278

  Monk, Brian C ^a   Harding, David R K ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b MASSEY UNIVERSITY   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); AMLODIPINE BESYLATE; AMPHOTERICIN B; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CALCIUM CHANNEL; CARDIAC GLYCOSIDE; CASPOFUNGIN; CEPHALOSPORIN; CLARATIN; DIGITALIS; EPIDERMAL GROWTH FACTOR; GEFITINIB; GLIPIZIDE; HISTAMINE H1 RECEPTOR; HISTAMINE H2 RECEPTOR; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; IMATINIB; LEUKOTRIENE RECEPTOR; LORATADINE; MICAFUNGIN; MILBEMYCIN; MONTELUKAST; NIKKOMYCIN Z; NISIN; OMEPRAZOLE; PENICILLIN G; POTASSIUM CHANNEL; RANITIDINE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ALLERGY; ASTHMA; BACTERIAL CELL WALL; BACTERIAL INFECTION; BREAST CANCER; CANCER CELL; CELL SURFACE; CELL TRANSPORT; COMBINATORIAL LIBRARY; COST EFFECTIVENESS ANALYSIS; DRUG RECEPTOR BINDING; DRUG RESISTANCE; DRUG SCREENING; DRUG TARGETING; DRUG TRANSPORT; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL STROMAL TUMOR; HEART INFARCTION; HEARTBURN; HUMAN; HYPERTENSION; INTERNALIZATION; LUNG CANCER; MEMBRANE BINDING; MEMBRANE TRANSPORT; MYCOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; REVIEW; STOMACH ULCER;

ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; DRUG DELIVERY SYSTEMS; DRUG INDUSTRY; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR MIMICRY; PEPTIDES;

EID: 26444454461     PISSN: 11738804     EISSN: 11738804     Source Type: Journal    
DOI: 10.2165/00063030-200519040-00005     Document Type: Review

References (147)

1. Jones D. Overcoming inhibition. Nat Rev Drug Discov 2004; 3: 551
2. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002; 53: 615-27
3. Fauci AS. Infectious diseases: considerations for the 21st Century. Clin Infect Dis 2001; 32: 675-85
4. Projan SJ. Why is big pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 2003; 6: 427-30
5. Levy SB. The antibiotic paradox. New York: Plenum Press, 1992: 7
6. Bush K. Why it is important to continue antibacterial drug discovery. ASM News 2004; 70: 282-7
7. Overbye KM, Barrett JF. Antibiotics: where did we go wrong? Drug Discov Today 2005; 10: 45-52
8. Shlaes DM, Projan SJ, Edwards JEJ. Antibiotic discovery: state of the state. ASM News 2004; 70: 275-81
9. Bush K, Macielag M, Weidner-Wells M. Taking inventory: antibacterial agents currently at or beyond phase 1. Curr Opin Microbiol 2004; 7: 466-76
10. Sams-Dodd F. Target-based drug discovery: is something wrong? Drug Discov Today 2005; 10: 139-47
11. Xia Y, Yu H, Jansen R, et al. Analyzing cellular biochemistry in terms of molecular networks. Annu Rev Biochem 2004; 73: 1051-87
12. Yamamoto K, Fujii R, Toyofuku Y, et al. The KDEL receptor mediates a retrieval mechanism that contributes to quality control at the endoplasmic reticulum. EMBO J 2001; 20: 3082-91
13. Morphy R, Kay C, Rankovic Z. From magic bullets to designed multiple ligands. Drug Discov Today 2004; 9: 641-51
14. De Backer MD, Ilyina T, Ma XJ, et al. Genomic profiling of the response of Candida albicans to itraconazole treatment using a DNA microarray. Antimicrob Agents Chemother 2001; 45: 1660-70
15. Agarwal AK, Rogers PD, Baerson SR, et al. Genome-wide expression profiling of the response to polyene, pyrimidine, azole, and echinocandin antifungal agents in Saccharomyces cerevisiae. J Biol Chem 2003; 278: 34998-5015
16. Monk BC, Cannon RD. Genomic pathways to antifungal discovery. Curr Drug Targets Infect Disord 2002; 2: 309-29
17. Bayles KW. The bactericidal action of penicillin: new clues to an unsolved mystery. Trends Microbiol 2000; 8: 274-8
18. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142-51
19. Monk BC, Perlin DS. Fungal plasma membrane proton pumps as promising new antifungal targets. Crit Rev Microbiol 1994; 20: 209-23
20. Weston SA, Camble R, Colls J, et al. Crystal structure of the anti-fungal target N-myristoyl transferase. Nat Struct Biol 1998; 5: 213-21
21. Sanglard D, Billie J. Current understanding of the modes of action and resistance mechanisms to conventional and emerging agents for the treatment of Candida infections. In: Calderone R, editor. Candida and candidiasis. Washington, DC: ASM Press, 2002: 349-83
22. Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46: 3-26
23. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002; 1: 727-30
24. Potoski J. Timely synthetic support for medicinal chemists. Drug Discov Today 2005; 10: 115-20
25. National Cancer Institute/National Institute of Health. Developmental therapeutics program [online]. Available from URL: http://dtp.nci.nih.gov/index. html [Accessed 2005 Jun 3]
26. Joseph SJ, Hugenholtz P, Sangwan P, et al. Laboratory cultivation of widespread and previously uncultured soil bacteria. Appl Environ Microbiol 2003; 69: 7210-5
27. Kaeberlein T, Lewis K, Epstein SS. Isolating 'uncultivable' microorganisms in pure culture in a simulated natural environment. Science 2002; 296: 1127-9
28. Zengler K, Toledo G, Rappe M, et al. Cultivating the uncultured. Proc Natl Acad Sci U S A 2002; 99: 15681-6
29. Handelsman J. Metagenomics: application of genomics to uncultured microorganisms. Microbiol Mol Biol Rev 2004; 68: 669-85
30. Schloss PD, Handelsman J. Biotechnological prospects from metagenomics. Curr Opin Biotechnol 2003; 14: 303-10
31. McDaniel R, Ebert-Khosla S, Hopwood DA, et al. Rational design of aromatic polyketide natural products by recombinant assembly of enzymatic subunits. Nature 1995; 375: 549-54
32. Maggio ET, Shenderovich M, Kagan R, et al. Structural pharmacogenomics, drug resistance and the design of anti-infective super-drugs. Drug Discov Today 2002; 7: 1214-20
33. Poole K. Mechanisms of bacterial biocide and antibiotic resistance. J Appl Microbiol 2002; 92 Suppl.: 55S-64S
34. Sanglard D. Resistance of human fungal pathogens to antifungal drugs. Curr Opin Microbiol 2002; 5: 379-85
35. Post FA, Willcox PA, Mathema B, et al. Genetic polymorphism in mycobacterium tuberculosis isolates from patients with chronic multidrug-resistant tuberculosis. J Infect Dis 2004; 190: 99-106
36. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998; 11: 382-402
37. White TC, Holleman S, Dy F, et al. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 2002; 46: 1704-13
38. Guillemard V, Saragovi HU. Novel approaches for targeted cancer therapy. Curr Cancer Drug Targets 2004; 4: 313-26
39. Arap W, Kolonin MG, Trepel M, et al. Steps toward mapping the human vascula-ture by phage display. Nat Med 2002; 8: 121-7
40. Oh P, Li Y, Yu J, et al. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 2004; 429: 629-35
41. Cutler JE. N-glycosylation of yeast, with emphasis on Candida albicans. Med Mycol 2001; 39 Suppl. 1: 75-86
42. Odds FC, Brown AJ, Gow NA. Antifungal agents: mechanisms of action. Trends Microbiol 2003; 11: 272-9
43. Chauhan N, Li D, Calderone R, et al. The cell wall of Candida species. In: Calderone R, editor. Candida and candidiasis. Washington, DC: ASM Press, 2002: 159-75
44. Malinska K, Malinsky J, Opekarova M, et al. Visualization of protein compartmentation within the plasma membrane of living yeast cells. Mol Biol Cell 2003; 14: 4427-36
45. Bagnat M, Keranen S, Shevchenko A, et al. Lipid rafts function in biosynthetic delivery of proteins to the cell surface in yeast. Proc Natl Acad Sci U S A 2000; 97: 3254-9
46. Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev 2003; 55: 27-55
47. Green DW. The bacterial cell wall as a source of antibacterial targets. Expert Opin Ther Targets 2002; 6: 1-19
48. Miyagi T, Wada T, Yamaguchi K, et al. Sialidase and malignancy: a mini review. Glycoconj J 2004; 20: 189-98
49. +-ATPase. Annu Rev Pharmacol Toxicol 1995; 35: 277-305
50. Parderu P, Park S, Perlin DS. Capsofungin uptake is mediated by a high-affinity transporter in Candida albicans. Antimicrob Agents Chemother 2004; 48: 3845-9
51. Sawyers C. Targeted cancer therapy. Nature 2004; 432: 294-7
52. Davies D. Understanding biofilm resistance to antibacterial agents. Nat Rev Drug Discov 2003; 2: 114-22
53. Drenkard E. Antimicrobial resistance of Pseudomonas aeruginosa biofilms. Microbes Infect 2003; 5: 1213-9
54. Kuhn DM, Ghannoum MA. Candida biofilms: antifungal resistance and emerging therapeutic options. Curr Opin Investig Drugs 2004; 5: 186-97
55. Friedrich C, Scott MG, Karunaratne N, et al. Salt-resistant alpha-helical cationic antimicrobial peptides. Antimicrob Agents Chemother 1999; 43: 1542-8
56. Ginsburg I. Bactericidal cationic peptides can also function as bacteriolysis-inducing agents mimicking beta-lactam antibiotics? It is enigmatic why this concept is consistently disregarded. Med Hypotheses 2004; 62: 367-74
57. Hancock RE, Patrzykat A. Clinical development of cationic antimicrobial peptides: from natural to novel antibiotics. Curr Drug Targets Infect Disord 2002; 2: 79-83
58. Reddy KV, Yedery RD, Aranha C. Antimicrobial peptides: premises and promises. Int J Antimicrob Agents 2004; 24: 536-47
59. Niimi K, Harding DR, Parshot R, et al. Chemosensitization of fluconazole resistance in Saccharomyces cerevisiae and pathogenic fungi by a D-octapeptide derivative. Antimicrob Agents Chemother 2004; 48: 1256-71
60. Monk BC, Niimi K, Lin S, et al. Surface-active fungicidal D-peptide inhibitors of the plasma membrane proton pump that block azole resistance. Antimicrob Agents Chemother 2005; 49: 57-70
61. Shadidi M, Sioud M. Selective targeting of cancer cells using synthetic peptides. Drug Resist Updat 2003; 6: 363-71
62. Tucker GC. Alpha v integrin inhibitors and cancer therapy. Curr Opin Investig Drugs 2003; 4: 722-31
63. Moffitt MC, Neilan BA. The expansion of mechanistic and organismic diversity associated with non-ribosomal peptides. FEMS Microbiol Lett 2000; 191: 159-67
64. Papagianni M. Ribosomally synthesized peptides with antimicrobial properties: biosynthesis, structure, function, and applications. Biotechnol Adv 2003; 21: 465-99
65. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002; 415: 389-95
66. Hancock RE, Diamond G. The role of cationic antimicrobial peptides in innate host defences. Trends Microbiol 2000; 8: 402-10
67. Hancock RE, Scott MG. The role of antimicrobial peptides in animal defenses. Proc Natl Acad Sci U S A 2000; 97: 8856-61
68. Yeaman MR, Yount NY. Code among chaos: immunorelativity and the AEGIS model of antimicrobial peptides. ASM News 2005; 71: 21-7
69. Yount NY, Yeaman MR. Multidimensional signatures in antimicrobial peptides. Proc Natl Acad Sci U S A 2004; 101: 7363-8
70. De Lucca AJ, Walsh TJ. Antifungal peptides: novel therapeutic compounds against emerging pathogens. Antimicrob Agents Chemother 1999; 43: 1-11
71. van't Hof W, Veerman EC, Helmerhorst EJ, et al. Antimicrobial peptides: properties and applicability. Biol Chem 2001; 382: 597-619
72. Hancock RE, Chapple DS. Peptide antibiotics. Antimicrob Agents Chemother 1999; 43: 1317-23
73. Andreu D, Ubach J, Boman A, et al. Shortened cecropin A-melittin hybrids: significant size reduction retains potent antibiotic activity. FEBS Lett 1992; 296: 190-4
74. Merrifield EL, Mitchell SA, Ubach J, et al. D-enantiomers of 15-residue cecropin A-melittin hybrids. Int J Pept Protein Res 1995; 46: 214-20
75. Merrifield RB, Juvvadi P, Andreu D, et al. Retro and retroenantio analogs of cecropin-melittin hybrids. Proc Natl Acad Sci U S A 1995; 92: 3449-53
76. Wade D, Andreu D, Mitchell SA, et al. Antibacterial peptides designed as analogs or hybrids of cecropins and melittin. Int J Pept Protein Res 1992; 40: 429-36
77. Fernandez-Lopez S, Kim HS, Choi EC, et al. Antibacterial agents based on the cyclic D,L-alpha-peptide architecture. Nature 2001; 412: 452-5
78. Thanou M, Florea BI, Langemeyer MW, et al. N-trimethylated chitosan chloride (TMC) improves the intestinal permeation of the peptide drug buserelin in vitro (Caco-2 cells) and in vivo (rats). Pharm Res 2000; 17: 27-31
79. Chung HH, Harms G, Seong CM, et al. Dendritic oligoguanidines as intracellular translocators. Biopolymers 2004; 76: 83-96
80. Ruissen AL, Groenink J, Helmerhorst EJ, et al. Effects of histatin 5 and derived peptides on Candida albicans. Biochem J 2001; 356: 361-8
81. Ulvatne H, Samuelsen O, Haukland HH, et al. Lactoferricin B inhibits bacterial macromolecular synthesis in Escherichia coli and Bacillus subtilis. FEMS Microbiol Lett 2004; 237: 377-84
82. Li XS, Reddy MS, Baev D, et al. Candida albicans Ssa1/2p is the cell envelope binding protein for human salivary histatin 5. J Biol Chem 2003; 278: 28553-61
83. Hamamoto K, Kida Y, Zhang Y, et al. Antimicrobial activity and stability to proteolysis of small linear cationic peptides with D-amino acid substitutions. Microbiol Immunol 2002; 46: 741-9
84. Palsdottir H, Hunte C. Lipids in membrane protein structures. Biochim Biophys Acta 2004; 1666: 2-18
85. Hancock RE. Peptide antibiotics. Lancet 1997; 349: 418-22
86. Peschel A, Otto M, Jack RW, et al. Inactivation of the dit operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J Biol Chem 1999; 274: 8405-10
87. Ganz T, Lehrer RI. Antibiotic peptides from higher eukaryotes: biology and applications. Mol Med Today 1999; 5: 292-7
88. Check W. Innate immunity depends on toll-like receptors. ASM News 2004; 70: 317-22
89. Mattsby-Baltzer I, Roseanu A, Motas C, et al. Lactoferrin or a fragment thereof inhibits the endotoxin-induced interleukin-6 response in human monocytic cells. Pediatr Res 1996; 40: 257-62
90. Shinoda I, Takase M, Fukuwatari Y, et al. Effects of lactoferrin and lactoferricin on the release of interleukin 8 from human polymorphonuclear leukocytes. Biosci Biotechnol Biochem 1996; 60: 521-3
91. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science 2004; 303: 1532-5
92. 2+-ATPases. Nature 1986; 319: 689-93
93. Ostresh JM, Blondelle SE, Dorner B, et al. Generation and use of nonsupport-bound peptide and peptidomimetic combinatorial libraries. Methods Enzymol 1996; 267: 220-34
94. Balzi E, Wang M, Leterme S, et al. PDR5, a novel yeast multidrug resistance conferring transporter controlled by the transcriptional regulator PDR1. J Biol Chem 1994; 269: 2206-14
95. Kolaczkowski M, van der Rest M, Cybularz-Kolaczkowski A, et al. Anticancer drugs, ionophoric peptides, and steroids as substrates of the yeast multidrug transporter Pdr5p. J Biol Chem 1996; 271: 31543-8
96. Decottignies A, Rogers B, Kowlaczkowski M, et al. The pleiotropic drug ABC transporters from Saccharomyces cerevisiae. In: Paulsen IT, Lewis K, editors. Microbial multidrug efflux. Wymondham: Horizon Scientific Press, 2002: 157-76
97. Ko KH, Lee CJ, Shin CY, et al. Inhibition of mucin release from airway goblet cells by polycationic peptides. Am J Physiol 1999; 277: L811-15
98. Lee CJ, Paik SH, Ko KH, et al. Effects of polycationic peptides on mucin release from airway goblet cells: relationship between polymer size and activity. Inflamm Res 2002; 51: 490-4
99. Bosshart H, Heinzelmann M. Endotoxin-neutralizing effects of histidine-rich peptides. FEBS Lett 2003; 553: 135-40
100. Steiner DF. The proprotein convertases. Curr Opin Chem Biol 1998; 2: 31-9
101. Molloy SS, Anderson ED, Jean F, et al. Bi-cycling the furin pathway: from TGN localization to pathogen activation and embryogenesis. Trends Cell Biol 1999; 9: 28-35
102. Cameron A, Appel J, Houghten RA, et al. Polyarginines are potent furin inhibitors. J Biol Chem 2000; 275: 36741-9
103. Kacprzak MM, Peinado JR, Than ME, et al. Inhibition of furin by polyarginine-containing peptides: nanomolar inhibition by nona-D-arginine. J Biol Chem 2004; 279: 36788-94
104. Mattner F, Fleitmann JK, Lingnau K, et al. Vaccination with poly-L-arginine as immunostimulant for peptide vaccines: induction of potent and long-lasting T-cell responses against cancer antigens. Cancer Res 2002; 62: 1477-80
105. Mitchell DJ, Kim DT, Steinman L, et al. Polyarginine enters cells more efficiently than other polycationic homopolymers. J Pept Res 2000; 56: 318-25
106. Rothbard JB, Kreider E, VanDeusen CL, et al. Arginine-rich molecular transporters for drug delivery: role of backbone spacing in cellular uptake. J Med Chem 2002; 45: 3612-8
107. Luedtke NW, Carmichael P, Tor Y. Cellular uptake of aminoglycosides, guanidinoglycosides, and poly-arginine. J Am Chem Soc 2003; 125: 12374-5
108. Kabouridis PS. Biological applications of protein transduction technology. Trends Biotechnol 2003; 21: 498-503
109. Lundberg P, Langel U. A brief introduction to cell-penetrating peptides. J Mol Recognit 2003; 16: 227-33
110. Midoux P, Kichler A, Boutin V, et al. Membrane permeabilization and efficient gene transfer by a peptide containing several histidines. Bioconjug Chem 1998; 9: 260-7
111. Temsamani J, Vidal P. The use of cell-penetrating peptides for drug delivery. Drug Discov Today 2004; 9: 1012-9
112. Fuchs SM, Raines RT. Pathway for polyarginine entry into mammalian cells. Biochemistry 2004; 43: 2438-44
113. Nah JW, Yu L, Han SO, et al. Artery wall binding peptide-poly(ethylene glycol)-grafted-poly(L-lysine)-based gene delivery to artery wall cells. J Control Release 2002; 78: 273-84
114. Sakharov DV, Jie AF, Bekkers ME, et al. Polylysine as a vehicle for extracellular matrix-targeted local drug delivery, providing high accumulation and long-term retention within the vascular wall. Arterioscler Thromb Vasc Biol 2001; 21: 943-8
115. Sakharov DV, Jie AF, Filippov DV, et al. Binding and retention of polycationic peptides and dendrimers in the vascular wall. FEBS Lett 2003; 537: 6-10
116. Mai JC, Mi Z, Kim SH, et al. A proapoptotic peptide for the treatment of solid tumors. Cancer Res 2001; 61: 7709-12
117. Pauletti GM, Okumu FW, Borchardt RT. Effect of size and charge on the passive diffusion of peptides across Caco-2 cell monolayers via the paracellular path-way. Pharm Res 1997; 14: 164-8
118. Landon LA, Deutscher SL. Combinatorial discovery of tumor targeting peptides using phage display. J Cell Biochem 2003; 90: 509-17
119. Trepel M, Arap W, Pasqualini R. In vivo phage display and vascular heterogeneity: implications for targeted medicine. Curr Opin Chem Biol 2002; 6: 399-404
120. Shadidi M, Sioud M. Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cells. FASEB J 2003; 17: 256-8
121. He HT, Xu CR, Song X, et al. Syntheses of cyclic prodrugs of RGD peptidomimetics with various macrocyclic ring sizes: evaluation of physicochemical, transport and antithrombic properties. J Pept Res 2003; 61: 331-42
122. Kelleman A, Mattern RH, Pierschbacher MD, et al. Incorporation of thioether building blocks into an alphavbeta3-specific RGD peptide: synthesis and biological activity. Biopolymers 2003; 71: 686-95
123. Rust WL, Carper SW, Plopper GE. The promise of integrins as effective targets for anticancer agents. J Biomed Biotechnol 2002; 2: 124-30
124. Fujii H, Nishikawa N, Komazawa H, et al. A new pseudo-peptide of Arg-Gly-Asp (RGD) with inhibitory effect on tumor metastasis and enzymatic degradation of extracellular matrix. Clin Exp Metastasis 1998; 16: 94-104
125. Tsuchiya Y, Sawada S, Tsukada K, et al. A new pseudo-peptide of Arg-Gly-Asp (RGD) inhibits intrahepatic metastasis of orthotopically implanted murine hepatocellular carcinoma. Int J Oncol 2002; 20: 319-24
126. Fujimoto K, Iwasaki C, Arai C, et al. Control of cell death by the smart polymeric vehicle. Biomacromolecules 2000; 1: 515-8
127. Lestini BJ, Sagnella SM, Xu Z, et al. Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery. J Control Release 2002; 78: 235-47
128. Xu CR, He HT, Song X, et al. Synthesis and comparison of physiochemical, transport and antithrombic properties of a cyclic prodrug and the parent RGD peptidomimetic. Tetrahedron 2003; 59: 2861-9
129. Chen Y, Xu X, Hong S, et al. RGD-Tachyplesin inhibits tumor growth. Cancer Res 2001; 61: 2434-8
130. Yokoyama Y, Ramakrishnan S. Addition of integrin binding sequence to a mutant human endostatin improves inhibition of tumor growth. Int J Cancer 2004; 111: 839-48
131. Marquez M, Nilsson S, Lennartsson L, et al. Charge-dependent targeting: results in six tumor cell lines. Anticancer Res 2004; 24: 1347-51
132. Litovchick A, Evdokimov AG, Lapidot A. Aminoglycoside-arginine conjugates that bind TAR RNA: synthesis, characterization, and antiviral activity. Biochemistry 2000; 39: 2838-52
133. Eubank TD, Biswas R, Jovanovic M, et al. Inhibition of bacterial RNase P by aminoglycoside-arginine conjugates. FEBS Lett 2002; 511: 107-12
134. Li Q, Lee JY, Castillo R, et al. NB2001, a novel antibacterial agent with broad-spectrum activity and enhanced potency against beta-lactamase-producing strains. Antimicrob Agents Chemother 2002; 46: 1262-8
135. Stone GW, Zhang Q, Castillo R, et al. Mechanism of action of NB2001 and NB2030, novel antibacterial agents activated by beta-lactamases. Antimicrob Agents Chemother 2004; 48: 477-83
136. Jiang T, Olson ES, Nguyen QT, et al. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci U S A 2004; 101: 17867-72
137. Cortez-Retamozo V, Backmann N, Senter PD, et al. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res 2004; 64: 2853-7
138. Stijlemans B, Conrath K, Cortez-Retamozo V, et al. Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies: African trypanosomes as paradigm. J Biol Chem 2004; 279: 1256-61
139. Grant GA, editor. Synthetic peptides: a user's guide. 2nd ed. Oxford, UK: Oxford University Press, 2002
140. Jois SD, Hughes R, Siahaan TJ. Comparison of the solution conformations of a cell-adhesive peptide LBE and its reverse sequence EBL. J Biomol Struct Dyn 1999; 17: 429-44
141. Hugo CP, Pichler RP, Schulze-Lohoff E, et al. Thrombospondin peptides are potent inhibitors of mesangial and glomerular endothelial cell proliferation in vitro and in vivo. Kidney Int 1999; 55: 2236-49
142. Guo NH, Krutzsch HC, Inman JK, et al. Antiproliferative and antitumor activities of D-reverse peptides derived from the second type-1 repeat of thrombospondin-1. J Pept Res 1997; 50: 210-21
143. Fenniri H. Combinatorial chemistry: a practical approach. Oxford, UK: Oxford University Press, 2000
144. Glattli AL, Seebach D, van Gunsteren WF. Do valine side chains have an influence on the folding behavior of β-substituted β-peptides? Helv Chim Acta 2004; 87: 2487-506
145. Lind R, Greenhow D, Perry S, et al. Comparative metabolism of α- and β-peptides in the insect Heliothis virescens and in plant cells of black mexican sweet maize. Chem Biodivers 2004; 1 (9): 1391-400
146. Seebach D, Beck AK, Bierbaum DJ, et al. The world of β- and γ-peptides comprised of homologated proteinogenic amino acids and other components. Chem Biodivers 2004; 1: 1111-239
147. Biltresse S, Attolini M, Dive G, et al. Novel RGD-like molecules based on the tyrosine template: design, synthesis, and biological evaluation on isolated integrins alpha(V)beta/alpha(IIb)beta(3) and in cellular adhesion tests. Bioorg Med Chem 2004; 12: 5379-93